Linperlisib: all 22 studies that test it
Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.
- Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell LymphomaNot yet recruitingNCT07209163Phase 1/2
- Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell LymphomaNot yet recruitingNCT07139353Phase 1/2
- Linperlisib in the Treatment of aPRCANot yet recruitingNCT07031115Phase 2
- Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)Not yet recruitingNCT06712173Phase 1
- A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell LymphomaNot yet recruitingNCT06548347Phase 2/3
- Linperlisib Combined With Chidamide in Patients With PTCLRecruitingNCT06421948Phase 1/2
- Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell LymphomaRecruitingNCT06376721Phase 1/2
- A National Multicenter, Real-world Study of Linperlisib in the Treatment of LymphomaNot yet recruitingNCT06343935Phase 4
- Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic LeukemiaRecruitingNCT06224257Phase 2
- A Umbrella Study in R/R PTCL Guided by Molecular SubtypesRecruitingNCT05559008Phase 1/2
- Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic LeukemiaCompletedNCT05676710Phase 1
- PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of TherapyTerminatedNCT05676697Phase 1
- A Study of Linperlisib Combination With Camrelizumab in Patients With Solid TumorStatus unknownNCT05429398Phase 1
- A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell LymphomaStatus unknownNCT05274997Phase 2
- A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell LymphomaStatus unknownNCT04705090Phase 2
- YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical TrialStatus unknownNCT04500561Phase 1/2
- A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular LymphomaStatus unknownNCT04379167Phase 2
- A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's LymphomaStatus unknownNCT04370405Phase 2
- A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic MalignanciesCompletedNCT04279405Phase 1
- A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaStatus unknownNCT04108325Phase 1
- A Phase I Study of YY-20394 in Patients With Advanced Solid TumorsStatus unknownNCT04049929Phase 1
- A Phase I Study of YY-20394 in Patients With B Cell Hematologic MalignanciesStatus unknownNCT03757000Phase 1